Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) Return-on-Tangible-Equity: 0.00% (As of . 20)


XTUN:SIPHA Societe des Industries Pharmaceutiques de Tunisie-S I PHA T XTUN:SIPHA
12 GF Score
Price TND4.00
! 1 Warning Sign
View Full Analysis

What is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Return-on-Tangible-Equity?

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T XTUN:SIPHA -2.44% 12 Return-on-Tangible-Equity is 0.00% as of . 20. GuruFocus rates XTUN:SIPHA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's annualized net income for the quarter that ended in . 20 was TND Mil. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's average shareholder tangible equity for the quarter that ended in . 20 was TND Mil. Therefore, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 was %.

The historical rank and industry rank for Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's Return-on-Tangible-Equity or its related term are showing as below:

XTUN:SIPHA's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.88
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T  (XTUN:SIPHA) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Return-on-Tangible-Equity Related Terms


Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Return-on-Tangible-Equity Chart

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Annual Data
Trend
Return-on-Tangible-Equity

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Semi-Annual Data
Return-on-Tangible-Equity

XTUN:SIPHA vs BIEI, PTXTQ, INQD: Return-on-Tangible-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Return-on-Tangible-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's Return-on-Tangible-Equity falls into.


XTUN:SIPHA
12GF Score
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T XTUN:SIPHA
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Return-on-Tangible-Equity Calculation

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's annualized Return-on-Tangible-Equity for the fiscal year that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( (+ )/ )
=/
= %

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (. 20) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) has a Return-on-Tangible-Equity of 0.00% as of . 20. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Societe des Industries Pharmaceutiques de Tunisie-S I PHA T and its competitors.
Is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's Return-on-Tangible-Equity too high?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's current Return-on-Tangible-Equity is 0.00%. Overall, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's Return-on-Tangible-Equity compare to BIEI and PTXTQ?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's Return-on-Tangible-Equity of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median Return-on-Tangible-Equity is 7.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.88, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Societe des Industries Pharmaceutiques de Tunisie-S I PHA T and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T stock overvalued right now?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA), the current Return-on-Tangible-Equity is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Business Description

Address Fondouk Choucha, Ben Arous, TUN, 2013
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T is a Tunisia-based company mainly engaged in manufacturing and distributing medicines and drugs. The company also has its own research and development process to develop generic drugs. It offers pharmaceutical, dietary, hygiene, and cosmetic products in dry, liquid and pasty forms.
12GF Score

Get the complete analysis for XTUN:SIPHA

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

TND4.00
Price